Osteoporosis associated with neuroleptic treatment. A case report
Abstract
A 28-year-old woman developed osteoporosis following seven years of neuroleptic use. She presented with amenorrhea and profuse galactorrhea of four years' duration. Dual photon absorptionometry demonstrated reduced bone mineral density in the femur and spine. Serum calcium, phosphorus and alkaline phosphatase were normal. The patient was started on bromocriptine, and her bone density, serum prolactin, dehydroepiandrosterone sulfate, and free and total testosterone improved. No deterioration in her psychiatric condition occurred.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Development of a crushable foam model for human trabecular bone
- Data-driven motion compensation in HR-pQCT.
- Modeling of structure, quality, and function in the orthodontic patient
- Exploring the mechanism of Heidihuang Pill in the treatment of osteoporosis based on network pharmacology, molecular docking, and experimental validation
- Effect of fabric on the accuracy of computed tomography-based finite element analyses of the vertebra
- Use of interventions involving virtual reality tasks during the climacteric: a systematic review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.